TRIM25 in Septic Patients

Condition(s) studied

Investigational drug(s) / intervention(s)

Gene and Inflammatory Marker Analysis in Sepsis: 1.Sepsis Group: 1. SOFA score \>=2; 2. Aged 18-70 years male and female; 3. Hospitalization. 2.Non-sepsis Group: (1) Healthy adults; (2) Aged 18-70 years male and female.

Study summary

Sepsis is a life-threatening condition caused by the body's overwhelming response to infection, which can lead to organ damage and failure. The goal of this observational study is to better understand the underlying biological changes that occur in patients with sepsis compared to those who do not have the condition.

We will collect peripheral blood samples from patients diagnosed with sepsis and from non-sepsis control participants. From these samples, we will isolate peripheral blood mononuclear cells (PBMCs) and serum.

We will then analyze these components to measure the activity of specific genes and the levels of key inflammatory factors (cytokines).

The information we gather will help researchers identify molecular and inflammatory markers associated with sepsis. This knowledge is crucial for developing new and more effective methods for diagnosing and treating this critical illness.

Eligibility

Primary outcome measure(s)

• TRIM25 in PBMCs — From 2021.12 to 2026.06
  We will collect peripheral blood mononuclear cells (PBMCs) from both sepsis patients and non-sepsis control patients to compare the expression level of the TRIM25 gene in these cells.

Trial sites (1)

More Ruijin Hospital trials in China

Other trials for the same condition